Valchlor

malignant effusion, Lymphoma, Chronic Lymphocytic Leukemia + 5 more
Treatment
20 Active Studies for Valchlor

What is Valchlor

MechlorethamineThe Generic name of this drug
Treatment SummaryMechlorethamine is an alkylating drug used to treat Hodgkin’s disease and lymphomas. It is a very strong irritant that can damage mucous membranes and cause severe gastrointestinal and bone marrow damage. The FDA approved Valchlor (mechlorethamine) gel in 2013 as an orphan drug to treat stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have already received skin-directed therapy. Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% of mechlorethamine hydrochlor
Mustargenis the brand name
Valchlor Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mustargen
Mechlorethamine
1949
5

Effectiveness

How Valchlor Affects PatientsMechlorethamine, sometimes known as mustine, nitrogen mustard, or HN2, is a drug used to treat cancer. It was originally developed from the research done on toxic gases used in warfare. It works by disrupting the DNA of the cancer cells and causing them to die.
How Valchlor works in the bodyAlkylating agents work by preventing DNA from being copied, transcribed, and separated. They do this by attaching groups to the DNA, forming cross-links, or inducing mispairing of DNA bases. Mechlorethamine specifically targets all phases of the cell cycle.

When to interrupt dosage

The endorsed measure of Valchlor is contingent upon the determined condition, including Polycythemia Vera (PV), Mycosis Fungoides (MF) and Stage I Mycosis Fungoides. The amount of dosage can be found in the table below, relative to the technique of delivery (e.g. Powder, for solution - Intracavitary; Intravenous or Intravenous).
Condition
Dosage
Administration
Chronic Lymphocytic Leukemia
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Topical, Gel, Gel - Topical, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Gel - Cutaneous, Cutaneous
Lymphoma
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Topical, Gel, Gel - Topical, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Gel - Cutaneous, Cutaneous
Hodgkin Disease
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Topical, Gel, Gel - Topical, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Gel - Cutaneous, Cutaneous
Carcinoma, Bronchogenic
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Topical, Gel, Gel - Topical, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Gel - Cutaneous, Cutaneous
malignant effusion
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Topical, Gel, Gel - Topical, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Gel - Cutaneous, Cutaneous
Mycosis Fungoides
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Topical, Gel, Gel - Topical, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Gel - Cutaneous, Cutaneous
Polycythemia Vera
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Topical, Gel, Gel - Topical, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Gel - Cutaneous, Cutaneous
Mycosis Fungoides
, 0.0012 mg/mg, 1.0 mg/mL, 10.0 mg, 0.00016 mg/mg
, Topical, Gel, Gel - Topical, Powder, for solution, Powder, for solution - Intracavitary; Intravenous, Intracavitary; Intravenous, Intravenous, Powder, for solution - Intravenous, Gel - Cutaneous, Cutaneous

Warnings

Valchlor has two contraindications, so it should not be administered in conjunction with the conditions specified in the following table.Valchlor Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Communicable Diseases
Do Not Combine
There are 20 known major drug interactions with Valchlor.
Common Valchlor Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Acteoside.
Valchlor Toxicity & Overdose RiskToo much exposure to the drug can cause serious decreases in white blood cells, red blood cells, and platelets, leading to difficulties with bleeding. Other common side effects include skin inflammation, itching, bacterial skin infection, ulcers or blisters, and darkening of the skin. The lowest toxic dose for a rat is 10mg/kg.

Valchlor Novel Uses: Which Conditions Have a Clinical Trial Featuring Valchlor?

Currently, 177 active clinical trials are being conducted to assess the efficacy of Valchlor in alleviating symptoms of malignant effusions, Stage I Mycosis Fungoides and Mycosis Fungoides (MF).
Condition
Clinical Trials
Trial Phases
Chronic Lymphocytic Leukemia
143 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4
Mycosis Fungoides
0 Actively Recruiting
Lymphoma
0 Actively Recruiting
malignant effusion
0 Actively Recruiting
Mycosis Fungoides
0 Actively Recruiting
Polycythemia Vera
0 Actively Recruiting
Carcinoma, Bronchogenic
0 Actively Recruiting
Hodgkin Disease
3 Actively Recruiting
Not Applicable, Phase 1

Valchlor Reviews: What are patients saying about Valchlor?

2.7Patient Review
1/29/2018
Valchlor for Chronic Malignant T-Cell Lymphoma of the Skin
This medication caused my skin to become severely irritated, and eventually led to a nasty infection. Even after the initial infection had healed, continuing treatment led to more severe irritation. Lowering the dosage helped somewhat, but even one dose causes inflammation and burning.

Patient Q&A Section about valchlor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Valchlor chemotherapy?

"The cancer chemotherapy drug mechlorethamine was originally developed to be used intravenously, but it is safe and effective when used topically in the form of Valchlor for early stage CTCL."

Answered by AI

What is Valchlor used for?

"The purpose of this medication is to treat cutaneous T-cell lymphoma, a type of cancer that affects the skin. Mechlorethamine is an alkylating agent, a class of drugs that work by slowing or stopping the growth of cancer cells."

Answered by AI

How much does Valchlor cost?

"The price of Valchlor topical gel 0.016% is approximately $5,502 for a supply of 60 grams, depending on the pharmacy you visit. This price is only for customers who pay in cash, and does not apply to those with insurance plans."

Answered by AI

How long does it take for Valchlor to work?

"After VALCHLOR is applied, it is absorbed into the skin and begins attacking cancerous lymphoma cells. The amount of time it takes for the medication to work can vary from person to person. Some people who responded to treatment saw results as early as 1 month, while others took up to 11 months."

Answered by AI

Clinical Trials for Valchlor

Image of Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center in Cleveland, United States.

Rituximab + Tafasitamab + NK Cells for Non-Hodgkin's Lymphoma

18+
All Sexes
Cleveland, OH
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death). Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.
Phase 1
Waitlist Available
Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center (+1 Sites)Paolo Caimi, MDIncyte Corporation
Image of City of Hope Medical Center in Duarte, United States.

Venetoclax + Obinutuzumab + Epcoritamab for Chronic Lymphocytic Leukemia

18+
All Sexes
Duarte, CA
This phase II trial tests the effect of venetoclax and obinutuzumab followed by epcoritamab in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have not previously received treatment. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Epcoritamab, a bispecific monoclonal antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. The combination of venetoclax and obinutuzumab is a standard treatment for CLL/SLL and has been found to be safe and effective. Adding epcoritamab to standard treatment with venetoclax and obinutuzumab may lead to deeper and longer-lasting responses in patients with untreated CLL/SLL.
Phase 2
Waitlist Available
City of Hope Medical Center (+6 Sites)Alexey V Danilov
Have you considered Valchlor clinical trials? We made a collection of clinical trials featuring Valchlor, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

CMV-MVA Triplex Vaccine for Cancer

18 - 75
All Sexes
Duarte, CA
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.
Phase 1
Waitlist Available
City of Hope Medical Center (+2 Sites)Ryotaro Nakamura
Have you considered Valchlor clinical trials? We made a collection of clinical trials featuring Valchlor, we think they might fit your search criteria.Go to Trials
Image of University of California Medical Center in San Francisco, United States.

Pirtobrutinib for Lymphoma

18+
All Sexes
San Francisco, CA
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Phase 4
Recruiting
University of California Medical Center (+18 Sites)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company
Have you considered Valchlor clinical trials? We made a collection of clinical trials featuring Valchlor, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security